Profile data is unavailable for this security.
About the company
Eton Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing treatments for rare diseases. The Company has five commercial rare disease products: ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. ALKINDI SPRINKLE is a granule hydrocortisone formulation designed to help provide accurate dosing for newborns and children with adrenal insufficiency. PKU GOLIKE is a next generation medical formula product engineered with the patent protected, pharmaceutical grade Physiomimic technology for the dietary management of phenylketonuria (PKU) under medical supervision. Carglumic Acid is used for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is developed for the treatment of homocystinuria.
- Revenue in USD (TTM)34.68m
- Net income in USD-5.48m
- Incorporated2017
- Employees30.00
- LocationEton Pharmaceuticals Inc21925 W Field Pkwy Ste 235DEER PARK 60010-7278United StatesUSA
- Phone+1 (847) 787-7361
- Websitehttps://etonpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Puma Biotechnology Inc | 243.57m | 23.24m | 142.35m | 185.00 | 6.11 | 2.00 | 4.09 | 0.5845 | 0.475 | 0.475 | 5.03 | 1.45 | 1.15 | 17.91 | 5.83 | 1,316,589.00 | 10.95 | -12.21 | 18.85 | -20.53 | 69.29 | 78.78 | 9.54 | -11.79 | 1.40 | 3.61 | 0.5234 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
| Elutia Inc | 24.78m | -60.29m | 152.07m | 54.00 | -- | -- | -- | 6.14 | -2.10 | -1.84 | 0.8695 | -1.16 | 0.4813 | 2.82 | 8.52 | 458,925.90 | -117.08 | -42.93 | -649.22 | -79.34 | 42.41 | 43.32 | -243.28 | -64.16 | 0.849 | -1.18 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
| LifeVantage Corp | 196.01m | 4.13m | 164.83m | 217.00 | 41.23 | 5.93 | 21.71 | 0.8409 | 0.3192 | 0.3192 | 15.27 | 2.22 | 3.06 | 2.50 | 71.64 | 903,290.30 | 6.46 | 9.95 | 10.17 | 15.55 | 79.21 | 81.45 | 2.11 | 3.08 | 0.9923 | 559.36 | 0.00 | 26.95 | -6.20 | -2.40 | 15.63 | -16.94 | -2.18 | -- |
| Scpharmaceuticals Inc | 30.28m | -80.12m | 173.10m | 135.00 | -- | 5.64 | -- | 5.72 | -1.91 | -1.91 | 0.7417 | 0.6137 | 0.262 | 0.7268 | 4.52 | 224,281.50 | -69.31 | -38.23 | -78.18 | -42.31 | 69.72 | -- | -264.60 | -1,360.16 | 6.89 | -8.42 | 0.6246 | -- | -- | -- | -48.79 | -- | -- | -- |
| Mediwound Ltd | 20.14m | -19.97m | 180.78m | 100.00 | -- | 8.71 | -- | 8.98 | -2.16 | -2.16 | 2.18 | 1.92 | 0.3311 | 5.53 | 6.55 | 201,410.00 | -32.83 | -24.48 | -49.28 | -32.92 | 13.25 | 43.27 | -99.17 | -38.43 | 1.51 | -3.26 | 0.2623 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| Inhibrx Biosciences Inc | 1.73m | 1.64bn | 202.37m | 166.00 | 0.117 | 1.13 | 0.123 | 116.71 | 119.47 | 119.47 | 0.0499 | 12.33 | 0.0058 | -- | 4.41 | 10,445.78 | 552.15 | -77.06 | 637.71 | -93.91 | -- | -- | 94,778.95 | -1,590.91 | -- | -45.76 | 0.00 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
| Biostem Technologies Inc | 210.39m | 14.32m | 219.71m | 67.00 | 21.41 | 9.65 | 15.11 | 1.04 | 0.6302 | 0.6302 | 10.58 | 1.40 | 3.82 | 8.46 | 5.01 | -- | 26.03 | -- | 135.75 | -- | 94.84 | -- | 6.81 | -- | 1.23 | 27.98 | 0.1576 | -- | -- | -- | -- | -- | -- | -- |
| Lifecore Biomedical Inc | 128.45m | 5.71m | 257.05m | 524.00 | 188.96 | -- | 17.86 | 2.00 | 0.0369 | 0.0595 | 3.82 | 1.28 | 0.5217 | 2.01 | 4.96 | 245,124.00 | 2.32 | -5.91 | 2.74 | -8.33 | 34.65 | 31.01 | 4.45 | -19.16 | 0.803 | 0.125 | 0.7641 | -- | 24.20 | -25.46 | 114.53 | 34.47 | -16.72 | -- |
| Precigen Inc | 3.96m | -139.56m | 257.82m | 202.00 | -- | 4.78 | -- | 65.06 | -0.5479 | -0.5479 | 0.0154 | 0.1891 | 0.0289 | -- | 5.40 | 19,618.81 | -101.81 | -31.50 | -126.84 | -38.63 | -12.44 | 44.00 | -3,521.68 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Eton Pharmaceuticals Inc | 34.68m | -5.48m | 277.74m | 30.00 | -- | 17.38 | -- | 8.01 | -0.2135 | -0.2135 | 1.34 | 0.6186 | 1.03 | 9.44 | 7.63 | 1,155,900.00 | -16.27 | -46.22 | -29.44 | -58.20 | 59.30 | 72.16 | -15.81 | -76.86 | 1.41 | -- | 0.2052 | -- | 48.90 | -- | 89.62 | -- | 26.85 | -- |
| Sanara Medtech Inc | 78.06m | -8.36m | 326.44m | 107.00 | -- | 8.20 | -- | 4.18 | -0.9871 | -0.9871 | 9.24 | 4.55 | 0.9518 | 1.91 | 8.39 | 729,503.40 | -10.33 | -17.73 | -12.37 | -22.07 | 90.16 | 88.08 | -10.86 | -17.13 | 2.02 | -3.44 | 0.4326 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Amylyx Pharmaceuticals Inc | 196.49m | -259.47m | 355.76m | 384.00 | -- | 1.81 | -- | 1.81 | -3.82 | -3.82 | 2.87 | 2.86 | 0.5479 | 2.56 | 12.64 | 511,679.70 | -72.35 | -- | -84.00 | -- | 78.88 | -- | -132.05 | -- | 4.55 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| Revance Therapeutics Inc | 247.00m | -180.81m | 402.83m | 597.00 | -- | -- | -- | 1.63 | -1.91 | -1.95 | 2.55 | -1.55 | 0.497 | 1.03 | 6.71 | 413,740.40 | -36.38 | -55.55 | -43.47 | -63.20 | 72.61 | -- | -73.20 | -304.96 | 3.05 | -15.40 | 1.58 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Aquestive Therapeutics Inc | 58.90m | -35.19m | 411.21m | 135.00 | -- | -- | -- | 6.98 | -0.4514 | -0.4514 | 0.7297 | -0.4982 | 0.6954 | 2.56 | 6.46 | 436,296.30 | -41.55 | -76.63 | -54.06 | -123.85 | 69.39 | 64.24 | -59.75 | -102.95 | 5.91 | -2.72 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
Data as of Nov 22 2024. Currency figures normalised to Eton Pharmaceuticals Inc's reporting currency: US Dollar USD
29.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Opaleye Management, Inc.as of 23 Oct 2024 | 2.85m | 11.04% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.02m | 3.94% |
| Nantahala Capital Management LLCas of 30 Sep 2024 | 998.73k | 3.87% |
| Westside Investment Management LLCas of 30 Jun 2024 | 585.40k | 2.27% |
| Acuitas Investments LLCas of 30 Sep 2024 | 579.96k | 2.25% |
| EcoR1 Capital, LLCas of 30 Sep 2024 | 566.08k | 2.19% |
| Paradigm Capital Management, Inc.as of 30 Sep 2024 | 300.00k | 1.16% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 281.00k | 1.09% |
| Geode Capital Management LLCas of 30 Sep 2024 | 272.70k | 1.06% |
| Parkman Healthcare Partners LLCas of 30 Sep 2024 | 260.23k | 1.01% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
